Fiala

Peptide library › Bone health

Vosoritide

Also known as Voxzogo

FDA-approved drugBone health

Daily injection that helps children with achondroplasia, the most common form of dwarfism, grow faster.

What people use it for

What Vosoritide does in the body

A modified version of C-type natriuretic peptide (CNP). It counteracts the overactive FGFR3 signal that slows bone growth at the growth plates in achondroplasia.

Strength of evidence

Moderate to strong: a Phase 3 trial showed faster yearly growth; effects on final adult height and health are still being studied.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2021 under accelerated approval, later extended to younger children. Continued approval may depend on further trials.

How it's taken

Route: Injection under the skin, once daily

How long it lasts (half-life): About 20 to 30 minutes

Storage

Refrigerated; can be kept at room temperature for a limited time.

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Vosoritide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Vosoritide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Bone health